Acadia Pharmaceuticals Inc

Health Care
Biotechnology: Pharmaceutical Preparations
www.acadia.com

Earnings Score
Moat Score

Market Cap $3.70B
PE 16
Debt -
Cash $217.70M
EV -
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$228.88M
EBIT	$264.85M
ROE	30%
ROA	23%
Equity	$765.24M
Growth Stability	1
PE	16.17
PEG	2.22
PB	4.84
P/S	3.72
Price/Cash	0.06
Net Margins	8%
Gross Margins	92%
Op. Margins	27%
Earnings CAGR	1%
Sales Growth YoY	19%
Sales Growth QoQ	-6%
Sales CAGR	62%
Equity CAGR	6%
Earnings Stability	0.01
Earnings Growth YoY	15%

Earnings Growth QoQ	-87%
Earnings CAGR 5Y	7%
Sales CAGR 5Y	45%
Equity CAGR 5Y	-1%
Earnings CAGR 3Y	34%
Sales CAGR 3Y	34%
Equity CAGR 3Y	25%
Market Cap	$3.70B
Revenue	$996.28M
Assets	$1.13B
Cash	$217.70M
Shares Outstanding	166.81M
Earnings Score	6%
Moat Score	94%
Working Capital	568.41M
Current Ratio	2.88
Gross Profit	$917.00M
Shares Growth 3y	1%
Equity Growth QoQ	4%
Equity Growth YoY	65%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

SEC Filings

Direct access to Acadia Pharmaceuticals Inc (ACAD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Acadia Pharmaceuticals Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Acadia Pharmaceuticals Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability 1%

loading chart...

Acadia Pharmaceuticals Inc Discounted Cash Flow

Fully customizable DCF calculator online for Acadia Pharmaceuticals Inc.

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-270K%	-2K%	-232%	-110%	-69%	-35%	-42%	-8%	24%	8%
ROA	-	-48%	-74%	-44%	-29%	-	-36%	-7%	22%	23%
ROE	-	-52%	-86%	-51%	-34%	-31%	-54%	-14%	31%	30%

Net Margins (7.77%)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	28K%	621%	79%	52%	43%	7%	40%	32%	45%
Earnings YoY growth	-	65%	7%	-15%	-4%	-29%	29%	-72%	-469%	7%
Equity YoY growth	-	160%	-35%	43%	46%	-23%	-26%	8%	70%	-1%
FCF YoY growth	-	69%	4%	-22%	-10%	-17%	-10%	-115%	844%	-